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Background: Neuroendocrine tumours (NETs) are rare in children and limited data are available. We aimed to specify tumour and
patient characteristics and to investigate the role of genetic predisposition in the aetiology of paediatric NETs.
Methods: Using the Dutch Pathology Registry PALGA, we collected patient- and tumour data of paediatric NETs in the
Netherlands between 1991 and 2013 (N¼ 483).
Results: The incidence of paediatric NETs in the Netherlands is 5.40 per one million per year. The majority of NETs were
appendiceal tumours (N¼ 441;91.3%). Additional surgery in appendiceal NETs was indicated in 89 patients, but performed in only
27 of these patients. Four out of five patients with pancreatic NETs were diagnosed with Von Hippel–Lindau disease (N¼ 2) and
Multiple Endocrine Neoplasia type 1 (N¼ 2). In one patient with an appendiceal NET Familial Adenomatous Polyposis was
diagnosed. On the basis of second primary tumours or other additional diagnoses, involvement of genetic predisposition was
suggestive in several others.
Conclusions: We identified a significant number of patients with a confirmed or suspected tumour predisposition syndrome and
show that paediatric pancreatic NETs in particular are associated with genetic syndromes. In addition, we conclude that treatment
guidelines for appendiceal paediatric NETs need revision and improved implementation.
A neuroendocrine tumour (NET) is a rare tumour with an
estimated incidence of 5.25 per 100 000 in adults (Yao et al, 2008;
Lawrence et al, 2011). The exact incidence of NETs in children is
not known, but a small study reported an incidence of 1.14 per one
million children (Parkes et al, 1993). In children, little research has
been performed on NETs with only small case-series of 2 to 36
patients reported (Kulkarni and Sergi, 2013).
Neuroendocrine tumours in children seem to differ from NETs
in adults. In adults, the most common locations of NETs are the
lungs and the gastrointestinal tract, specifically the rectum and
small intestine (Yao et al, 2008). In children, NETs are most
commonly found in the appendix (87.5%; Fernandez et al, 2015),
whereas in adults the incidence of NETs in the appendix is
relatively low (3% of all NETs; Yao et al, 2008). Appendiceal NETs
in children are indolent tumours which rarely metastasise and have
an excellent overall survival close to 100% (Kulkarni and Sergi,
2013). Survival in adults depends on the localisation of the NET
and disease stage at diagnosis (Yao et al, 2008). The 5-year survival
rate of localised appendiceal NETs is 88% (Yao et al, 2008), which
is less than the estimated survival in children.
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Genetic predisposition may have a role in the development of
NETs. These tumours have been reported as part of various
hereditary cancer syndromes as shown in Table 1, and familial
occurrence of NETs has also been reported in the absence of these
syndromes (Hemminki and Li, 2001). In addition, adults diagnosed
with a NET have an increased risk of developing second primary
malignancies (Babovic-Vuksanovic et al, 1999). These character-
istics are suggestive for hitherto unrecognised genetic predisposing
factors involved in the development of NETs in adults.
On the basis of the findings in adult studies, we suspect genetic
tumour predisposition syndromes might have a role in the aetiology
of NETs in children as well. To support this hypothesis we studied
the occurrence of second primary malignancies and the presence of
additional features or diagnoses in children with a NET.
Here we describe a large study of NETs in 483 children in the
Netherlands using PALGA, the nationwide pathology database.
The first aim of this study was to provide an overview of patient
and tumour characteristics in children with a NET. The collected
data also enabled us to study the adherence to surgical guidelines in
children with appendiceal NETs. Second, we aimed to find evidence
to support our hypothesis that genetic tumour predisposition is a
contributing factor in the aetiology of NETs. To our knowledge, this
is the largest case-series described in the literature so far.
MATERIALS AND METHODS
We retrospectively collected our data from PALGA, the nationwide
network and registry of histopathology and cytopathology
(Casparie et al, 2007) which encompasses all pathology reports
from all hospitals in the Netherlands since 1991. To obtain data
from all children in the Netherlands with a NET, we performed a
search with the search terms ‘carcinoid’ OR ‘neuroendocrine
tumour’ with limitations to the ages 0–18. This search resulted in
data from 505 children who were diagnosed with a NET between
1991 and 2013. In the Bosman et al (2010) and in our national
guidelines no diagnostic requirements for the diagnosis of a NET
are defined. Diagnosis was based on HE staining in unequivocal
cases and additional immunohistochemical staining if deemed
necessary by the pathologist, as is in daily practice. Data were
processed de-identified and contained 1105 excerpts in total.
Information about age at diagnosis, gender, localisation of the
tumour, tumour size, presence of metastasis, surgical treatment
and presence of additional features or diagnoses was extracted. The
file also included the data about other conditions for which a
pathologist was consulted that occurred prior to or in follow-up of
the NET. Many reports included the data on the medical history of
the child, which could shed light on conditions for which
examination by a pathologist was not necessary.
A total of 22 patients were excluded from the final analysis; six
because data were incomplete and 16 due to another diagnosis.
Patients in the latter group did not have a NET, but a different
tumour with neuroendocrine characteristics or a different type of
tumour with a NET only in the initial differential diagnosis.
Patient characteristics were compared using crosstabs in conjunc-
tion with a standard Pearson chi-square test. Statistical significance
was considered to exist if two-sided P-values were below 0.01. The
incidence of NETs was calculated by dividing the number of children
with a NET by the total Dutch childhood population for each of the
years between 2009 to 2013 (available at statline.cbs.nl). The average
incidence is based on these 5 years. Statistical analysis was carried out
using the SPSS statistical package (IBM Corp, 2013). Both the privacy
committee and the scientific committee of PALGA approved the
study design. Because of the strict anonymity, no additional ethical
approval was required.
RESULTS
Patient and tumour characteristics. A total of 483 patients (174
males and 309 females) were included in the analysis. The mean
follow-up of patients was 143 months (median 146 months, range
2–275 months). From 1991 to 2013 on average 21 children (range
14–26) were diagnosed with a NET per year in the Netherlands,
which averages an incidence rate of 5.40 per million children per
year. The median age of patients at the time of diagnosis was 15
years (range 1–18 years) and NETs were more frequently seen in
girls. We found a male : female ratio of 1 : 1.78. We observed no
difference in age at diagnosis by sex or by primary tumour
localisation. Details regarding age at diagnosis and the distribution
of tumour localisation are presented in Table 2.
Table 1. NETs in hereditary tumour predisposition syndromes
Tumour predisposition
syndrome Type of NETs Other features Reference
MEN-1 Duodeno-pancreatic (54–61%)
Bronchial (3.1–3.2%)
Thymic (2.6–6%; in men only)
Primary hyperparathyroidism
Pituitary tumours
Adrenal tumours
(Goudet et al, 2011; Goudet et al, 2009)
VHL Pancreatic (12.3–17%), mostly
non-functioning
Renal cell carcinoma
Pheochromocytoma
Hemangioblastoma
Pancreatic lesions (cystic and solid)
(Blansfield et al, 2007; Hammel et al, 2000)
NF1 Somatostatinoma
Insulinoma
Duodenal (o1%)
Cafe´-au-lait macules
Neurofibromas
Optic glioma
Iris hamartomas
(Anlauf et al, 2007; Lodish and Stratakis, 2010)
Tuberous sclerosis Pancreatic (o1%) Hamartomatous lesions in brain, skin, eyes,
heart, lungs and kidneys
(Anlauf et al, 2007; Lodish and Stratakis, 2010)
Lynch syndrome Small intestine
Appendix
Colorectal adenocarcinomas
Endometrial-, stomach- and urinary tract
tumours
(Miquel et al, 2004; Rodriguez-Bigas et al, 1998)
FAP Gastrointestinal tract Adenomatous polyps
Colorectal carcinoma
Extraintestinal tumours
(Camp et al, 2004; July et al, 1999)
Abbreviations: FAP¼ familial adenomatous polyposis; MEN-1¼multiple endocrine neoplasia type 1; NET¼neuroendocrine tumour; NF1¼ neurofibromatosis type 1; VHL¼Von Hippel–Lindau
syndrome.
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Appendiceal NETs were observed most frequently (441 patients,
91.3%), followed by bronchopulmonary tumours (25 patients,
5.2%). Two patients presented with a NET localised in another
(benign) tumour: a NET in a mature cystic teratoma and a NET in
a mature sacrococcygeal teratoma. In one patient with liver
metastasis of a NET, the primary tumour could not be identified.
The localisations of the primary tumours in the patients varied
significantly by sex, with increased incidence of appendiceal NETs
in females (95.1% vs 84.5%, Po0.001) and increased incidence of
bronchopulmonary NETs in male patients (10.3% vs 2.3%,
Po0.001). The distribution of gender related to tumour location
is shown in Table 3.
Metastatic disease. At the time of diagnosis, the majority of
patients did not have metastatic disease (N¼ 467, 96.7%). In 13
patients (2.7%) locoregional lymph node metastasis was present. In
three patients (0.6%), distant metastasis to the liver was found. Of
these patients one had a primary NET in the stomach and the
second a NET in a mature cystic teratoma. In the third patient with
distant metastasis the primary tumour was not identified after an
extensive search including multiple stomach biopsies and an
appendectomy. Appendiceal NETs metastasise significantly less
than NETs in other locations (Po0.001). Extended patient and
tumour characteristics of patients with metastatic disease are
described in Supplementary Table 1.
Appendiceal tumours. We found the appendix to be the most
common location of a NET in children (n¼ 441, 91.3%).
Histopathological data of the appendiceal NETs are presented in
Table 4. Four patients had multiple NETs in the appendix, with a
maximum of four NETs in one appendix (Table 5). All but two
patients presented with clinical symptoms of an acute abdomen,
suggestive of appendicitis. In the remaining two patients, the
appendiceal NETs were incidentally found during surgery for
another indication: a patient with Crohn’s disease underwent an
ileocecal resection and a patient with Familial adenomatous
polyposis (FAP) underwent a proctocolectomy. In 403 patients,
Table 2. Age and disease stage at diagnosis of NETs by gender and primary tumour site
Age at diagnosis in years Disease stage; N (%)
N (%) Median Range Localised Regional Distant
Gender
Male 174 (36.0) 15.0 6–18 165 (94.8) 8 (4.6) 1 (0.6)
Female 309 (64.0) 15.0 1–18 302 (97.7) 5 (1.6) 2 (0.6)
Primary tumour site
Appendix 441 (91.3) 14.4 4–18 434 (98.4) 7 (1.6) –
Lung 25 (5.2) 14.9 10–18 21 (84.0) 4 (16.0) –
Colon 5 (1.0) 14.0 2–18 4 (80.0) 1 (20.0) –
Pancreasa 4 (0.8) 15.5 14–17 4 (100.0) – –
Stomach 4 (0.8) 17.5 16–18 2 (50.0) 1 (25.0) 1 (25.0)
In other tumour 2 (0.4) 9.5 1–18 1 (50.0) – 1 (50.0)
Small intestine 1 (0.2) 16.0 – 1 (100.0) – –
Unknown 1 (0.2) 17.0 – – – 1 (100.0)
Abbreviation: NET¼ neuroendocrine tumour.
aIn total, 5 patients had a pancreatic NET, but in one patient this pancreatic NET occurred years after the diagnosis of a stomach NET.
This table describes only the primary tumour site.
Table 3. Distribution of gender related to localisation of the
tumour
Male Female
N % N % Pa
Primary tumour site
Appendix 147 84.5 294 95.1 o0.001
Lung 18 10.3 7 2.3 o0.001
Colon 3 1.7 2 0.6
Pancreas 2 1.2 2 0.6
Stomach 3 1.7 1 0.3
In other tumour 0 0.0 2 0.6
Small intestine 1 0.6 0 0.0
Unknown 0 0.0 1 0.3
Total 174 100 309 100
aP-values could not be calculated for the other tumour sites, since patient number were too
small.
Table 4. Histopathological data of NETs
N %a
Appendiceal NETs (n¼441)
Localisation of tumour
Base of the appendix 19 4.9
Apex/mid-region of the appendix 366 95.1
Totalb 385 100
Histology grade
Grade 1 152 98.1
Grade 2 3 1.9
Total 155 100
Tumour size
o10 mm 222 61.5
10–20 mm 128 35.5
420 mm 11 3.0
Total 361 100
Invasion of mesoappendix
Yes 83 22.6
No 282 76.6
Questionable 3 0.8
Total 368 100
Complete resection?
Yes 365 94.8
No 16 4.2
Questionable 4 1.0
Total 385 100
NETs outside the appendix (n¼42)
Histology grade
Grade 1 30 88.2
Grade 2 4 11.8
Total 34 100
Complete resection?
Yes 25 73.5
No 6 17.6
Questionable 3 8.8
Total 34 100
aPercentages are calculated based on the available data per tumour characteristic.
bDifferences in total numbers per subheading are due to missing data.
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an appendectomy was performed without additional surgery. In 33
patients an additional hemicolectomy or ileocecal resection was
performed.
Genetic predisposition. Genetic tumour predisposition can be
suspected when a child has multiple primary tumours, multiple
NETs or specific additional features or diagnoses that could indicate
genetic predisposition. A total of 18 patients in our cohort matched
these criteria (Table 5). In six patients (1.2%) a second primary
malignancy was found. Two of these patients had Von Hippel–Lindau
disease (VHL) and one was clinically diagnosed with Multiple
Endocrine Neoplasia syndrome type 1 (MEN-1), although from the
PALGA report we learned that a causative mutation had not yet been
identified. Three patients with an appendiceal NET (0.6%) had
additional premalignant lesions. One patient had multiple adenoma-
tous polyps of low to intermediate grade dysplasia in the colon and in
this patient the tumour predisposition syndrome FAP was diagnosed.
The other patient had CIN2 moderate dysplasia of the cervix at a
remarkably young age of 17 years. The third patient had a dysplastic
naevus, also at a very young age of 10 years.
Five patients (1.0%) presented with multiple NETs in the same
organ. Four had multiple appendiceal NETs and one patient had
multiple pancreatic NETs. This latter patient also had a MEN-1
diagnosis. Four other patients had additional features or diagnoses
that have been described in tumour predisposition syndromes
before, that is pilomatrixomas, multiple angiolipomas and an
osteoma. We found a high incidence of Crohn’s disease or strongly
suspected inflammatory bowel disease in 9 patients (1.9%, 2
confirmed, 7 patients suspected). An overview of all additional
diagnoses found in our cohort is available in Supplementary Table 2.
DISCUSSION
To our knowledge, this is the largest case-series of NETs in
children described in literature and we were able to confirm
previously reported characteristics of these tumours. In addition,
our results suggest that genetic tumour predisposition has an
important role in the aetiology of NETs in children, as we found
proven and strongly suspected genetic tumour predisposition
syndromes in 18 children.
The incidence of 5.40 per one million children per year in the
Netherlands is higher than the estimated incidence of 1.14 per million
children (Parkes et al, 1993). The incidence we report is probably more
realistic since we conducted a nationwide study. In line with previous
studies, we found that the appendix is by far the most common site
for NETs in children (Neves et al, 2006). Tumour localisation varied
significantly between sexes with females developing significantly more
appendiceal NETs then males. This may be explained by the increased
lifetime risk for a female to undergo an appendectomy (23.1% vs 12.0%
for males; Addiss et al, 1990) with consequently more incidental
findings of appendiceal NETs. It is unknown whether this explanation
is also applicable to the childhood population. Compared with females,
males develop more bronchopulmonary NETs. Strikingly, in adult
studies, females develop more bronchopulmonary NETs (Modlin
et al, 2003; Yao et al, 2008). We do not have an explanation for the
predilection of bronchopulmonary NETs in males in our cohort.
However, the number of pulmonary tumours we found is relatively
small and this finding needs confirmation.
A NET in children is reported to have a relatively indolent
disease course (Spunt et al, 2000; Kulkarni and Sergi, 2013). Data
about survival are lacking in our study due to the study design,
however only a few patients developed locoregional lymph node
metastases (N¼ 13) or distant metastases (N¼ 3). NETs in the
stomach, colon, lungs and NETs localised in different tumours
seem to metastasise more often (50, 20, 16 and 50%, respectively).
Because these localisations are rare in children these percentages
are based on small numbers and therefore the strength of this
observation may be questionable. However, stricter surveillance in
children with these tumour localisations seems warranted.
Exact guidelines for the surgical treatment of appendiceal NETs
in children are not available. In adult patients, a right-sided
hemicolectomy or an ileocecal resection is advised when
histopathological risk factors are present, according to the ENETS
Table 5. Patients with syndromes or features indicative of genetic cancer predisposition
No. Gender
Primary NET, age
in years Additional features or diagnoses (age in years)
Tumour predisposition
syndrome
Follow-up in
months
Patients with multiple primary malignancies
1 Male Pancreas, 17 Bilateral renal cell carcinoma (21) VHL confirmed 163
2 Male Appendix, 14 Myeloproliferative disease (23), probably chronic idiopathic myelofibrosis No 158
3 Male Stomach, 18 Multiple pancreatic NETs (29); no metastasis from stomach NET
Parathyroid hyperplasia
Clinical MEN-1, mutation
not found
146
4 Male Appendix, 14 Anaplastic T-cell lymphoma (26), dysplastic nevus (29) No 247
5 Female Pancreas, 16 Cerebellar hemangioblastoma (22) VHL confirmed 150
6 Female Appendix, 15 Adenoid cystic carcinoma breast (17) No 261
Patients with premalignant lesions at a remarkably young age
7 Male Appendix, 17 Multiple adenomatous polyps of low to intermediate grade dysplasia FAP confirmed 235
8 Female Appendix, 16 CIN2 moderate dysplasia of the cervix (17) No 49
9 Female Appendix, 17 Dysplastic nevus (10) No 143
Patients with multiple NETs
10 Male Pancreas, 14 Two pancreatic NETs and pancreatic microadenomatosis
Parathyroid hyperplasia
MEN-1 confirmed 57
11 Female Appendix, 17 Two NETs in the appendix, 7 mm (top) and 8 mm (base) No 100
12 Male Appendix, 17 Two NETs in the appendix, 16 mm (top) and 4 mm (base) No 223
13 Female Appendix, 17 Two NETs in the appendix, 3 mm and 8mm No 53
14 Female Appendix, 13 Four NETs in the appendix, sizes unknown No 4
Patients with other features that could indicate genetic predisposition
15 Female Appendix, 18 Osteoma of the ear No 23
16 Female Appendix, 16 Pilomatrixoma (18) No 116
17 Male Lung, 12 Pilomatrixoma (15) No 130
18 Male Lung, 18 Nine angiolipomas (22) No 139
Abbreviations: CIN¼ cervical intra-epithelial neoplasia; FAP¼ familial adenomatous polyposis; MEN-1¼multiple endocrine neoplasia syndrome type 1; NET¼ neuroendocrine tumour;
VHL¼Von Hippel–Lindau disease.
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consensus treatment guidelines for neuroendocrine tumours of the
appendix (Pape et al, 2016). The ENETS consensus guidelines state
that additional surgery is indicated when one of the following
criteria is present: tumour size 42 cm, invasion of the mesoap-
pendix, localisation of the tumour at the base of the appendix or an
incomplete initial resection of the tumour (Pape et al, 2016). On
the basis of these criteria additional surgery was indicated in 89
patients with appendiceal NETs, but performed in only 27 of these
patients. Six patients had additional surgery, although there was no
strict indication according to these guidelines. It is noteworthy that
these treatment guidelines were not available in the early nineties,
so they are not applicable for our entire cohort. No clear difference
was seen between the group of patients in whom additional surgery
was performed, compared with the group of patients in whom
additional surgery was not performed. On the other hand, six
patients did have additional surgery despite the fact that it was not
indicated based on the tumour characteristics. The role of
additional surgery in the management of patients with appendiceal
NETs is controversial, particularly in children and adolescents, as
NETs in these patients tend to behave less aggressively (Safioleas
et al, 2005). Indeed, none of the 62 patients who did not undergo
additional surgery developed histological proven metastatic disease
during follow-up. Perhaps clinicians consider these guidelines to
extreme for these tumours in children and therefore they opt for a
less invasive treatment. The development of a guideline for surgical
treatment in children with appendiceal NETs may help find more
consensus on this subject.
We found a significant number of patients (N¼ 18, 3.7%;
Table 5) in whom a genetic tumour predisposition syndrome was
diagnosed or strongly suspected. Genetic predisposition can be
suspected based on several factors, like for instance the presence of
multiple primary tumours in a patient (Moppett et al, 2001) and
cancer in combination with specific features that fit one of the
known tumour predisposition syndromes, such as specific skin
lesions (e.g., cafe´-au-lait macules in neurofibromatosis) or
congenital anomalies (Merks et al, 2008). Finally, a family history
of cancer could be indicative of genetic predisposition. Unfortu-
nately, data about family history were unavailable in our study.
A total of six patients developed a second primary malignancy
(SPM) during the period of observation (1.2%). None of these
malignancies was treatment related since none of these children
received chemotherapy or radiotherapy. Therefore, these children
had an indication for genetic counselling and genetic testing (Moppett
et al, 2001). In three of these children, we indeed found evidence for a
known cancer predisposing syndrome (Table 5). The two tumour
predisposition syndromes VHL and MEN-1 occurred in a much
higher incidence in our cohort than in the general population (1 : 242
vs 1 : 36 000 (Lonser et al, 2003) and 1 : 242 vs 1 : 50 000 (Brandi et al,
2001), respectively; Po0.001 for both comparisons). All of these
patients had pancreatic NETs, which suggests pancreatic NETs in
particular are highly associated with tumour predisposition syndromes.
We could not confirm that a genetic predisposition syndrome was
present in the other three children with multiple malignancies, which
does not necessarily mean that such a diagnosis has not been made. In
particular, genetic tumour predisposition is likely to have a role in the
patient with an adenoid cystic breast carcinoma at age 17, since this is
a tumour that is very unusual in childhood. Mean age at diagnosis of
this tumour is 63 years (Ghabach et al, 2010) and to our knowledge, no
case reports of this tumour in children have been described.
In studies on SPMs in adult patients with gastrointestinal NETs,
the incidence of SPMs ranges from 12–46% (Habal et al, 2000). In
children, only one retrospective study was performed and no SPMs
were identified (Fernandez et al, 2015). However, this study was
rather small and contained a cohort of only 32 patients with a short
median follow-up of 84 months. Even though our follow-up was
relatively short in many of the patients (median of 143 months,
range 2–275) we identified 6 patients with a SPM. If follow-up
would be extended, it is possible that more SPMs at relatively
young age will be identified.
We have identified one child with FAP and several children with
Crohn’s disease in our cohort. Neuroendocrine tumours in FAP
and Crohn’s disease have been described before (July et al, 1999;
West et al, 2007; Pratico et al, 2013). We found an incidence of
Crohn’s disease or strongly suspected inflammatory bowel disease
of 0.4–1.9% (400–1900 per 100 000) which is significantly higher
than the incidence of Crohn’s disease in the general paediatric
population (6.6 per 100 000; Po0.001; Adamiak et al, 2013). The
most important explanation for the association between Crohn’s
disease and NETs is probably the higher number of colectomies
performed in children with these conditions, which can result in the
incidental finding of a NET (Derikx et al, 2016). The hypothesis that
inflammation causes hyperstimulation of endocrine cells leading to
hyperplasia and neoplasia remains to be proven (West et al, 2007).
A third explanation might be that genetic predisposing factors for
FAP and Crohn also predispose for developing NETs.
The other remarkable findings shown in Table 5 are features
that are not previously reported in patients with NETs, but some
are associated with tumour predisposition syndromes in which
NETs have been described. For example, pilomatrixomas and
osteomas have been described in FAP (Bisgaard and Bulow, 2006;
Trufant et al, 2012). Since these are all rare findings in children, the
combination with childhood cancer may suggest the presence of a
genetic predisposition syndrome. Possibly even more patients have
interesting additional diagnoses, but using PALGA as our main
source of information we missed the patients with additional
diagnoses of which no biopsy was taken or tissue removed.
CONCLUSION
We identified several patients with a confirmed or suspected tumour
predisposition syndrome and showed that paediatric pancreatic NETs
in particular are associated with tumour predisposition syndromes,
since 4 out of 5 patients with a pancreatic NET had such a syndrome.
The presence of a pancreatic NET in a child should therefore warrant
genetic counselling, genetic testing and surveillance advises in line
with the results of genetic testing. Studies including exome- or
genome-wide genetic testing are needed to further identify the role of
genetic predisposition in the aetiology of NETs.
In addition, we found that the current treatment guidelines need
revision and improved implementation in light of the much better
prognosis of appendiceal NETs in children compared with adults.
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